JPH0235057A - Functional food - Google Patents
Functional foodInfo
- Publication number
- JPH0235057A JPH0235057A JP63139677A JP13967788A JPH0235057A JP H0235057 A JPH0235057 A JP H0235057A JP 63139677 A JP63139677 A JP 63139677A JP 13967788 A JP13967788 A JP 13967788A JP H0235057 A JPH0235057 A JP H0235057A
- Authority
- JP
- Japan
- Prior art keywords
- carnosine
- day
- functional food
- drink
- functional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013376 functional food Nutrition 0.000 title claims description 29
- 108010087806 Carnosine Proteins 0.000 claims abstract description 78
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 78
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 77
- 230000000694 effects Effects 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 9
- 208000035755 Psychosomatic disease Diseases 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims description 15
- 230000005855 radiation Effects 0.000 claims description 8
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 208000002847 Surgical Wound Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000001647 drug administration Methods 0.000 claims description 2
- 230000003779 hair growth Effects 0.000 claims description 2
- 238000005728 strengthening Methods 0.000 claims description 2
- 230000003712 anti-aging effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 20
- 235000013305 food Nutrition 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 8
- 238000011084 recovery Methods 0.000 abstract description 7
- 230000002787 reinforcement Effects 0.000 abstract 2
- 230000009758 senescence Effects 0.000 abstract 2
- 230000001133 acceleration Effects 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 230000001256 tonic effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 238000001356 surgical procedure Methods 0.000 description 17
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 230000032683 aging Effects 0.000 description 10
- 230000036528 appetite Effects 0.000 description 10
- 235000019789 appetite Nutrition 0.000 description 10
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 10
- 229940044199 carnosine Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 9
- 230000035790 physiological processes and functions Effects 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 229960002885 histidine Drugs 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000035876 healing Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000002519 immonomodulatory effect Effects 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 208000012545 Psychophysiologic disease Diseases 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 229940000635 beta-alanine Drugs 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000013632 homeostatic process Effects 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- -1 lipid peroxide Chemical class 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 208000004044 Hypesthesia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 201000007741 female breast cancer Diseases 0.000 description 3
- 201000002276 female breast carcinoma Diseases 0.000 description 3
- 235000021552 granulated sugar Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 208000034783 hypoesthesia Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000000386 athletic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000014109 instant soup Nutrition 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 231100000668 minimum lethal dose Toxicity 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000009935 visceral pain Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- GEVGRLPYQJTKKS-UHFFFAOYSA-N 3-(phenylmethoxycarbonylamino)propanoic acid Chemical compound OC(=O)CCNC(=O)OCC1=CC=CC=C1 GEVGRLPYQJTKKS-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010071840 Cytosol nonspecific dipeptidase Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- BXRMEWOQUXOLDH-LURJTMIESA-N L-Histidine methyl ester Chemical compound COC(=O)[C@@H](N)CC1=CN=CN1 BXRMEWOQUXOLDH-LURJTMIESA-N 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000021156 lunch Nutrition 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明はＬ−カルノシンまたはその塩を必須成分として
含有する機能性食品に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to a functional food containing L-carnosine or a salt thereof as an essential ingredient.
従来の技術
食品にはこれまで栄養に関する一次機能と味覚に関する
二次機能の二つがあると考えられてきた。Conventional technical foods have been thought to have two functions: a primary function related to nutrition and a secondary function related to taste.
しかし最近になって食品の三次機能として栄養機能とは
別に生体機能を調節する働きも備えていることがわかり
、そのような働きを顕著に発揮するように加工した食品
を機能性食品と分類するようになった。本明細書をとお
して、機能性食品という用語をこのような三次機能を有
する食品に対して使用する。However, it has recently been discovered that foods have a tertiary function that regulates biological functions in addition to nutritional functions, and foods that have been processed to significantly exert such functions are classified as functional foods. It became so. Throughout this specification, the term functional food is used for foods with such tertiary functions.
１８６０年のドイツ帝国時代にリービッヒ肉エキスの商
品名でａ縮した肉エキスがインスタントスーブの素とし
て市販されていた。１９００年に帝政ロシアの化学者ダ
レウィッチはリービッヒ肉エキスを分析して成る塩基性
化合物を発見し、この物質をカルノシンと命名した（現
在***で市販されている肉エキスにはＬ−カルノシンを
約２．８％含有する）。その後、このし−カルノシンは
β−アラニンとＬ−ヒスチジンとより成り立つペプタイ
ドであることが同定され、合成も可能となった。現在で
はＬ−ヒスチジンを醗酵法で大量に供給できるようにな
ったので、Ｌ−カルノシンは動物質からの抽出に依存せ
ず、合成による供給が可能となった。Ｌ−カルノシンは
哺乳動物の骨格筋中に０．１〜０．２％含有されている
生理物質であり、我が国民の好む食品の鰻には０．５％
も含有されている。かくも大量に骨格筋中に含有されて
いる生理物質がいかなる生理学的、生化学的存在意義を
もつのか、或いは薬物としての有用性について、Ｌ−カ
ルノシンの発見以来今日までこれらに関する５５０編以
上の研究論文が発表されているにもかかわらず、その生
理学的、生化学的存在意義および薬理的を用件は発見で
きなかった。In 1860, during the German Empire, a reduced meat extract was commercially available as a base for instant soup under the trade name Liebig Meat Extract. In 1900, Dalewich, a chemist in imperial Russia, analyzed Liebig's meat extract and discovered a basic compound, which he named carnosine. 2.8%). Later, it was identified that carnosine is a peptide consisting of β-alanine and L-histidine, and its synthesis became possible. Nowadays, L-histidine can be supplied in large quantities by fermentation, so L-carnosine can be supplied synthetically without relying on extraction from animal matter. L-carnosine is a physiological substance that is contained in the skeletal muscles of mammals at 0.1-0.2%, and in eel, which is a favorite food of our people, it is 0.5%.
is also included. Since the discovery of L-carnosine, more than 550 articles have been published on the physiological and biochemical significance of the physiological substances contained in skeletal muscle in such large quantities, and their usefulness as drugs. Although research papers have been published, no findings have been made regarding its physiological, biochemical significance, or pharmacological properties.
動物界では最高にＬ−カルノシンを含有する鰻が、わが
国では疾病の治癒を促進し、健康を増進する食品として
定着し、年間８万トン、すなわち乳幼児を含めて国民−
人当たり４匹消費されている（中串約１８０ｇでＬ−カ
ルノシン約０．９ｇを含有する）。鰻料理は焼いた後蒸
し上げる方法が習慣となっているが、蒸す際に滴下する
エキス分は古来民間療法として病後、手術後の回復、離
床を早め、また肺疾患治療に有効であるとして根強く民
衆に伝承されてきた。この蒸し溜まりに含まれるし一力
ルノシンの量は処理された鰻の量と、溜まりの濃縮程度
によって大きく異なるが、測定の結果によれば、最低０
．１％から最高１．５％である。しかしながら鰻および
蒸し溜まり液の医療効果について、含有するビタミンＥ
によるとの説はあるが未だし一カルノシンの作用を追求
した研究はない。Eel, which contains the highest amount of L-carnosine in the animal kingdom, has become established in Japan as a food that promotes the healing of diseases and improves health.
Four pieces are consumed per person (approximately 180 g of medium skewer contains approximately 0.9 g of L-carnosine). It is customary for eel dishes to be grilled and then steamed, and the extract that is dripped during steaming has been used as a folk remedy since ancient times, and is believed to be effective in recovering from illness, surgery, and getting out of bed, as well as being effective in treating lung diseases. It has been handed down to the people. The amount of Shiichiriki lunosine contained in this steamed pool varies greatly depending on the amount of eel processed and the degree of concentration of the pool, but according to the measurement results, it is at least 0.
．． 1% to a maximum of 1.5%. However, regarding the medical effects of eel and steamed water, the vitamin E it contains
Although there is a theory that this is the case, there has been no research that has investigated the effects of carnosine.
本発明者らは民間に伝承されている効果の未だ解・明さ
れていない鰻の薬物としての作用はＬ−カルノシンによ
るものと推測していたが、このＬ−カルノシンの薬理作
用を解明し、Ｌ−カルノシンを高濃度に含有する機能性
食品を創製することが本発明の目的である。The present inventors had speculated that the folkloric effect of eel as a drug, which has not yet been explained or clarified, was due to L-carnosine. It is an object of the present invention to create a functional food containing a high concentration of L-carnosine.
〔課題を解決するための手段および作用〕本発明者らは
多年にわたり生理的に含まれるω−アミノ酸の生理活性
作用の研究中、その誘導体り一力ルノシンに熱傷治癒作
用のあることを発見した（特開昭５３−１２７８３５号
公報、熱傷の治療剤）。またその作用機序がＬ−カルノ
シンの組織修復促進作用（Ｓｕｒｇｅｒｙ１００二８１
５−８２１．１９８６）および免疫調節作用（特開昭６
１−１８６３２２号公報、［ＪＳＰ ４．１１７．７１
６）によることを同定した。またザルコーマ１８０移植
癌の増殖による免疫低下に対してこれを賦活し癌に抵抗
することを発見した（特開昭６０−１６９３４号公報）
。さらに抗腫瘍剤のＭＭＣ，５−ＦＬＩ、 抗生物質
のプレオマイシン、抗炎症剤のハイドロコーチシンおよ
び免疫抑制剤のＣＰＤの投与、Ｔ線の照射、ザルコーマ
１８０実験癌の移植などによって低下した免疫を非特異
的に賦活すること、さらに４０週齢以上の老化動物の生
理的に４０％低下した免疫をほぼ８０％に有意に賦活す
ることを見出した。Ｌ−力ル／シンには組織修復、免疫
調節作用、マクロファージ貧食機能活性化作用、白血球
減少の回復作用などの防衛機能を増強する積分作用があ
ることも解明した。[Means and effects for solving the problem] The present inventors have been researching the physiologically active effects of physiologically contained ω-amino acids for many years, and discovered that its derivative lunosine has a burn healing effect. (Japanese Unexamined Patent Publication No. 127835/1983, therapeutic agent for burns). The mechanism of action is L-carnosine's tissue repair promoting effect (Surgery 100281).
5-821.1986) and immunomodulatory effect (JP-A-6
1-186322, [JSP 4.117.71
6). They also discovered that sarcoma 180 can be activated to counteract the weakened immune system caused by the proliferation of transplanted cancers, thereby resisting cancer (Japanese Patent Laid-open Publication No. 16934/1982).
. In addition, the immune system was weakened by administration of antitumor agents MMC and 5-FLI, antibiotic pleomycin, anti-inflammatory agent hydrocortiscin, and immunosuppressant CPD, T-ray irradiation, and transplantation of Sarcoma 180 experimental cancer. It has been found that it non-specifically activates the immune system, and that it significantly activates the physiologically reduced immunity of aged animals aged 40 weeks or older by approximately 80% by approximately 40%. It has also been revealed that L-Ryru/Syn has an integral action to enhance defense functions such as tissue repair, immunomodulatory action, activation of macrophage phagocytic function, and recovery action from leukopenia.
さらにＬ−カルノシンの薬理作用も確認することができ
たので、痔疾患の治療剤（特開昭５８−１０３３２１号
公報）、湿疹性皮膚疾患および薬疹治療剤（特開昭５８
−１６４５１６号公報）として、またＬ−カルノシン坐
薬が子宮瞳部びらん症に優れた治療作用のあることも見
出して（特開昭５９−１１０６１９号公報、Ｕ Ｓ Ｐ
４．４４６．１４９＞特許出願した。In addition, we were able to confirm the pharmacological effects of L-carnosine, which led to a treatment for hemorrhoids (Japanese Unexamined Patent Publication No. 58-103321), a treatment for eczema skin diseases and drug eruptions (Japanese Unexamined Patent Publication No. 58-103321).
It was also discovered that L-carnosine suppositories have an excellent therapeutic effect on uterine pupil erosion (Japanese Unexamined Patent Publication No. 59-110619, U.S.P.
4.446.149> Patent application filed.
その他巨大外科浸襲の予後の創傷治癒を急速に進め、予
後の生理機能の再建を速やかに進め、早期離床を可能に
する効果、巨大侵襲後の免疫力の回復、創傷治癒を速や
かに完了する効果、癌疾患に由来する心身症を治癒し、
抗腫瘍剤投与による副作用の虚脱、嘔吐、食欲不振、無
動力、放射線による副作用の虚脱、食欲不振、無動力、
頭痛、めまい、冷汗、興奮、不安、不眠、宿酔症状など
を予防し、白血球数を維持回復し、生理機能を維持し再
建する効果を確認した。Others: Rapidly promotes wound healing in the prognosis of a major surgical invasion, promptly promotes the reconstruction of physiological functions in the prognosis, enables early ambulation, restores immunity after a major surgical invasion, and quickly completes wound healing. Effective, cures psychosomatic disorders caused by cancer diseases,
Side effects of anti-tumor drug administration include weakness, vomiting, loss of appetite, and apathy; side effects of radiation include weakness, loss of appetite, and apathy;
It was confirmed to be effective in preventing headaches, dizziness, cold sweats, excitement, anxiety, insomnia, and symptoms of hangover, maintaining and recovering white blood cell counts, and maintaining and reconstructing physiological functions.
上記のとおり、従来に類例のない自然治癒促進機能を持
つし一カルノシンの薬理学的有用性が本発明者らにより
解明されてきたが、これを必須成分として含有する機能
性食品は現在まで存在していない。本発明者らは、Ｌ−
カルノシンは人類が必須アミノ酸し−ヒスチジンの供給
源として日常動物性食品から大量に摂取してきた栄養源
の生理的ペプタイドで極めて無害中の物質であること、
および自然治癒を促進する薬理作用やすぐれた臨床効果
を与えることに注目し、Ｌ−カルノシンの食品への応用
に想到した。本発明者らはＬ−カルノシンを含有する機
能性食品をつくり、これを日常摂取させて、優れた生体
機能調節作用を発揮することを確認して本発明を完成す
るに至った。As mentioned above, the present inventors have elucidated the pharmacological usefulness of carnosine, which has an unprecedented natural healing promoting function, but to date there are no functional foods containing carnosine as an essential ingredient. I haven't. The inventors have discovered that L-
Carnosine is an extremely harmless physiological peptide that humans consume in large quantities from animal foods on a daily basis as a source of the essential amino acid, histidine.
Focusing on its pharmacological action to promote natural healing and excellent clinical effects, the inventors came up with the idea of applying L-carnosine to foods. The present inventors have completed the present invention by creating a functional food containing L-carnosine, and confirming that it exerts an excellent biological function regulating effect when ingested on a daily basis.
Ｌ−カルノシンは融点２５０℃（分解）、〔α］ ＝
＋２０．４）’ （Ｈ，Ｏ）で、無味、無臭の水に溶け
やすい白色結晶状粉末である。つぎの構造式で表される
。L-carnosine has a melting point of 250°C (decomposition), [α] =
+20.4)' (H,O), and is a tasteless, odorless white crystalline powder that is easily soluble in water. It is represented by the following structural formula.
ＨＣ＝ Ｃ−ＨＣ２ＣＨＣＯＯＨ
その水溶液はｐＨ８，０〜８．５である。Ｌ−カルノシ
ンは諸種の哺乳動物の、主として骨格筋に約０．１〜０
′、２％含有されている物質で、日常食品として食肉よ
り摂取され、必須アミノ酸し−ヒスチジンとβ−アラニ
ンとから生合成される。摂取されたし一力ルノシンは吸
収機力ルノシナーゼによりＬ−ヒスチジンとβ−アラニ
ンに分解されてＬ−ヒスチジンは栄養素となり、β−ア
ラニンは急速に代謝***され、一部はＬ−カルノシンに
再合成される〔Ｌ−カルノシン生合成の中間物質として
β−アラニル−１−メチル−ヒスチジン（Ａｎｓｅｒｉ
ｎｅ）がある〕。上記のごとくＬ−カルノシンは食品類
似の安全性の楊めて高い物質であり、吸収後は諸臓器中
に存在するカルノシナーゼにより分解されるので、多く
の医薬品が肝臓で代謝され、肝機能の負担となるのとは
全く異なる物質である。HC=C-HC2CHCOOH The aqueous solution has a pH of 8.0-8.5. L-carnosine is present in various mammals, mainly in skeletal muscles, at a concentration of approximately 0.1 to 0.
It is a substance that contains 2% of the amino acids, is ingested from meat as a daily food, and is biosynthesized from the essential amino acids - histidine and β-alanine. Ingested lunosine is broken down into L-histidine and β-alanine by the absorption mechanism lunosinase, L-histidine becomes a nutrient, β-alanine is rapidly metabolized and excreted, and a portion is resynthesized into L-carnosine. β-alanyl-1-methyl-histidine (Anseri
ne)]. As mentioned above, L-carnosine is a highly safe substance that is similar to food, and after being absorbed, it is broken down by carnosinase present in various organs, so many pharmaceuticals are metabolized in the liver and place a burden on liver function. It is a completely different substance from that.
つぎにＬ−カルノシンの急性毒性について述べる。Next, the acute toxicity of L-carnosine will be described.
急性毒性
マウスを、１群１０匹として種々の容量のし一力ルノシ
ンを腹腔内ならびに経口的に投与し、投与後５時間の急
性毒性症状を観察した。ＬＤ、。は７２時間後の死亡数
よりファンデアウ゛エルデン（Ｖａｎ ｄｅｒ Ｗａｅ
ｒｄｅｎ）法により算出した。Ｌ−カルノシンは投与液
量が０．１〜０．３ｍｆ／ １０ ｇ （７ウス）にな
るように生理食塩水に溶解した。Acutely toxic mice (10 mice per group) were administered various doses of lunosine intraperitoneally and orally, and symptoms of acute toxicity were observed 5 hours after administration. L.D. is based on the number of deaths after 72 hours.
It was calculated by the (rden) method. L-carnosine was dissolved in physiological saline so that the amount of solution administered was 0.1 to 0.3 mf/10 g (7 mu).
Ｌ−カルノシンの中毒症状としては１５．０００ｍｇ
／ ｋｇ腹腔内投与（ＬＤ＋ｏｏ）後約３０分頃より自
発運動の低下を招き復位をとり呼吸数は減少して不整と
なるが、正向反射あるいは逃避反射の消失はみられず、
時々挙尾反応を示したり間代性痙彎の発現をみるものが
半数にみられた。さらに症状が進むと横転を繰り返し、
接触刺激に対して反射が昂進し痙彎の誘発がみられるよ
うになり、強直性痙彎に移行し死に至った。１時間３０
分後に半数、２時間後に８０％、５時間後には金側が死
亡した。１５．０００ ｍｇ／ｋｇの経口投与後では殆
ど影響を示さなかったが、１２時間後に１０例中１例の
死亡を認めた。L-carnosine toxicity symptoms are 15,000mg.
Approximately 30 minutes after intraperitoneal administration (LD + oo), the patient began to lose his locomotor activity and returned to the standing position, and his breathing rate decreased and became irregular, but no loss of righting reflex or withdrawal reflex was observed.
Half of the subjects showed occasional tail-raising reactions or developed clonic convulsions. As the symptoms progress further, the patient may repeatedly roll over,
In response to contact stimulation, the reflex became exaggerated and convulsions were induced, which progressed to tonic convulsions and led to death. 1 hour 30
Half of them died after a minute, 80% died after two hours, and the gold side died after five hours. After oral administration of 15,000 mg/kg, almost no effect was observed, but death was observed in 1 out of 10 patients 12 hours later.
第１表
ＤＤＹマウスに対する急性毒性（７２時間値）は表に示
すとおりであり、Ｌ−カルノシンは極めて安全性の高い
化合物であるといえる。The acute toxicity (72 hour value) to DDY mice in Table 1 is as shown in the table, and it can be said that L-carnosine is an extremely safe compound.
安全域Ｒについて考慮すると、Ｌ−カルノシンのＬＤｓ
ｏ＞ ９，０８７ｍｇ／ｋｇ ｉ、ｐ、 （最小致死量
）および本発明者らの行った動物実験の結果による免疫
調節作用の至適用量の１００ ｍｇ／ｋｇｉ、 ｐ、か
ら計算するとＲ〉９０である。至適用量から計算すると
成人−日量は５ｇであり、経口投与ではその１０倍の５
０ｇまで許容されるが、実際の臨床経験からすると外科
創傷、疾病予後の健康維持或いは老年者が健康維持を目
的に日常経口摂取して充分な効果を発揮する一日の摂取
量は１０〜２０ｍｇ／ｋｇ（成人０．５〜１．．Ｏｇ／
日）であり、ＬＤＳＯ＞１４．９３０ ｍｇ／ｋｇ （
ｐ、ｏ、最小致死量）ニヨッテ安全域を計算するとＲ＞
７４６〜１４９３となる。Considering the safety margin R, the LDs of L-carnosine
Calculated from o > 9,087 mg/kg i,p, (minimum lethal dose) and 100 mg/kgi, p, the optimal dose for immunomodulatory effect according to the results of animal experiments conducted by the present inventors, R>90 It is. Calculating from the optimal dose, the daily dose for adults is 5g, which is 10 times that amount for oral administration.
Although it is permissible up to 0g, based on actual clinical experience, the daily intake for the purpose of maintaining good health for surgical wounds, disease prognosis, or elderly people to maintain good health is 10 to 20mg per day. /kg (adults 0.5-1.0g/
day) and LDSO>14.930 mg/kg (
p, o, minimum lethal dose) When calculating the Niyotte safety margin, R>
746-1493.
また抗腫瘍剤、放射線照射による免疫能の強い低下に対
しホメオスタシスを治療的に賦活する場合でも成人の一
日の摂取量は４〜５ｇ（８０〜１００ ｍｇ／ｋｇ）
、すなわちＲ＞１８６〜１４９である。これらの数値は
いずれもし一力ルノシンを含む機能性食品が食品として
過剰に飽食されたとしてもなお充分な安全域を示す数値
である。In addition, even when therapeutically activating homeostasis due to anti-tumor drugs or radiation irradiation, the daily intake for adults is 4 to 5 g (80 to 100 mg/kg).
, that is, R>186-149. All of these values indicate a sufficient safety margin even if the functional food containing lunosine is eaten excessively as a food.
Ｌ−カルノシンの合成法は公知であり（Ｊｏｕｒｎａｌ
ｏｆ Ｂｉｏｌｏｇｉｃａｌ Ｃｈｅｍｉｓｔｒｙ、
、 １０８． ｐｐ７５３．１９３５）、カルボベンズ
オキシβ−アラニンを五塩化りんでクロライドとし、メ
タノールでメチルエステルに導き、ヒドロアザイドを経
てアザイドとなし、Ｌ−ヒスチジン メチルエステルと
カップリングし、最後に接触還元によりカルボベンズオ
キシ基をはずすことによってＬ−カルノシンを得ること
ができる。本発明はＬ−カルノシンの塩を必須成分とす
る機能性食品をも包含するが、Ｌ−カルノシンの塩とし
てはカルボン酸基に基づく塩と、アミノ基に基づく、薬
理学上許容される酸との酸付加塩があり、またカルボン
酸基とアミノ基の双方に基づく塩がある。カルボン酸に
基づ（塩にはナトリウム、カリウム、カルシウム、マグ
ネシウム、亜鉛、アルミニウムおよびゲルマニウムのよ
うな金属との塩、アンモニウム塩および置換アンモニウ
ム塩、例えばトリエチルアミンのようなトリアルキルア
ミンその他のアミンとの塩があり、アミノ基に基づく塩
には塩酸、硫酸、リン酸、酢酸、プロピオン酸、乳酸、
酒石酸、クエン酸、コハク酸、マレイン酸、ベンゼンス
ルホン酸、トルエンスルホン酸などの無機酸、有機酸と
の塩があるが、これらはそれ自体公知の方法により、遊
離のし一力ルノシンを化学量論的に計算された量の、選
択された酸または塩基と反応させることによって製造す
ることができる。またＬ−カルノシンは上記のような金
属の水酸化物であってもよい。The synthesis method of L-carnosine is known (Journal
of Biological Chemistry,
, 108. pp753.1935), carbobenzoxy β-alanine was converted to chloride with phosphorus pentachloride, converted to methyl ester with methanol, converted to azide via hydroazide, coupled with L-histidine methyl ester, and finally converted to carbobenzyl by catalytic reduction. L-carnosine can be obtained by removing the oxy group. The present invention also includes functional foods containing salts of L-carnosine as an essential ingredient, but salts of L-carnosine include salts based on carboxylic acid groups and pharmacologically acceptable acids based on amino groups. There are acid addition salts of , as well as salts based on both carboxylic acid and amino groups. Based on carboxylic acids (salts include salts with metals such as sodium, potassium, calcium, magnesium, zinc, aluminum and germanium, ammonium salts and substituted ammonium salts, salts with trialkylamines such as triethylamine and other amines) Salts based on amino groups include hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, propionic acid, lactic acid,
There are salts with inorganic acids and organic acids such as tartaric acid, citric acid, succinic acid, maleic acid, benzenesulfonic acid, and toluenesulfonic acid. It can be prepared by reacting with a theoretically calculated amount of the selected acid or base. Further, L-carnosine may be a metal hydroxide as described above.
Ｌ−カルノシンを必須成分として含有する機能性食品を
つくるには動物性基源のＬ−カルノシン濃厚抽出物を用
いることが可能である。Ｌ−カルノシンは１９６９年か
ら１９年以上にわたりメルク・イゴダ社からＣａｒｎｉ
ｂｉｏｎの商品名でスペイン国で保健用一般薬として市
販されていたもので（−８１ｇ内服が保健用として能書
に記載されている）、安全性について実績がある生理的
ペプタイドである。このＬ−カルノシンは醗酵法のＬ−
ヒスチジンを合成母体としたもので、原材料としてわが
国から１９年間に約４，０００ｋｇ以上（浜理薬品■製
造、味の素側販売）輸出されていた。安全性については
このように既に長期間の臨床的実績があり経験済である
。したがって、合成り一カルノシンを用いることが機能
性食品として供給するうえで原材料の供給が容易であり
、安価に機能性食品として提供し得る方法である。あと
に述べる試験例でも合成品を使用した。酵素反応などに
よる生化学操作、さらにはバイオテクノロジーを応用し
て生物工学的操作などにより製造されたＬカルノシンを
使用してもよい。To produce functional foods containing L-carnosine as an essential component, it is possible to use concentrated extracts of L-carnosine from animal sources. L-carnosine was manufactured by Merck-Igoda for over 19 years starting in 1969.
It is a physiological peptide that has been marketed as a general health drug in Spain under the brand name ``bion'' (-81g orally is listed on the label as a health drug) and has a proven safety record. This L-carnosine is produced by the fermentation method.
It is a synthetic substance based on histidine, and more than 4,000 kg (manufactured by Hamari Pharmaceutical ■, sold by Ajinomoto) have been exported from Japan as a raw material over the past 19 years. As for safety, it has already been clinically proven over a long period of time and has been well-experienced. Therefore, using synthetic carnosine makes it easy to supply raw materials for supplying it as a functional food, and it is a method that can be provided as a functional food at a low cost. A synthetic product was also used in the test examples described later. L-carnosine produced by biochemical operations such as enzymatic reactions or biotechnological operations applying biotechnology may also be used.
Ｌ−カルノシンの構成成分はβ−アラニンとＬ−ヒスチ
ジンという生体内アミノ酸であり、安全性も高く、副作
用の心配がなく、また人体に対する吸収もよいので、Ｌ
−カルノシンを必須成分とする一機能性食品は安心して
摂取することがきる。The constituent components of L-carnosine are β-alanine and L-histidine, amino acids in the body, which are highly safe, have no side effects, and are well absorbed by the human body.
- Monofunctional foods containing carnosine as an essential ingredient can be safely consumed.
本発明者らの行った動物実験の結果によれば、Ｌ−カル
ノシンの１００ ｍｇ／ｋｇ／ １日１．ｐ、が免疫調
節作用の至適用量である。通常用いる腹腔内投与量から
経口投与量への換算率は１０倍であるがヒトに対する使
用量を少なく考慮して同量とすれば、体重５０ｋｇの成
人が機能性食品として摂取出来るし一カルノシンの量は
５ｇ／日という値が得られる。試験例では放射線、化学
療法剤による副作用の除去、予防のために２〜４ｇ／日
、心身症の治療には１〜２ｇ／日が摂取されている。ま
た老化に対しては０．５〜Ｉｇ／日が摂取されている。According to the results of animal experiments conducted by the present inventors, 100 mg/kg/day of L-carnosine 1. p, is the optimal dose for immunomodulatory effect. The conversion rate from the normally used intraperitoneal dose to the oral dose is 10 times, but if the same amount is taken into account, an adult weighing 50 kg can consume it as a functional food, and one carnosine. A value of 5 g/day is obtained. In test cases, 2 to 4 g/day was taken to eliminate and prevent side effects caused by radiation and chemotherapy, and 1 to 2 g/day was taken to treat psychosomatic disorders. Also, for aging, 0.5 to Ig/day is taken.
機能性食品をつくる場合０．１〜５ｇ／日程度のし−カ
ルノシンを摂取できるような任意の食品形態とすればよ
い。食品形態としては例えばジャム、ママレード、ドロ
ップ、フリン、セリ−、ヒスケラト、サンドウィッチ、
チョコレート、菓子、パン、バター、チューブ入りクリ
ーム、病人用特別食、味噌、醤油、即席スープ、ドリン
ク剤などの食品形態を例示することができるが、これら
を症状に応じ、嗜好に合わせてそれぞれ単独で、または
組み合わせで患者に摂取させる。また自然治癒の強化を
目的として、医師の食事箋に基づく栄養士の管理の下に
、病院給食の調理の際に任意の食品にＬ−カルノシン粉
末を加え、その場で調整した機能性食品の形態で患者に
与えることもできる。また本発明の機能性食品にはビタ
ミン剤やホルモン剤その他の栄養剤を混入させてもよい
。つぎに本発明の機能性食品の典型的な形態、摂取量お
よび摂取方法を例示する。When preparing a functional food, it may be in any food form that allows intake of about 0.1 to 5 g/day of carnosine. Examples of food forms include jam, marmalade, drops, furin, celery, hiskerato, sandwiches,
Examples of food forms include chocolate, confectionery, bread, butter, cream in tubes, special food for the sick, miso, soy sauce, instant soup, and drinks; or in combination with the patient. In addition, for the purpose of strengthening natural healing, L-carnosine powder is added to any food during the preparation of hospital lunches under the supervision of a nutritionist based on the doctor's dietary prescription, and the form of functional food is prepared on the spot. It can also be given to patients. Further, the functional food of the present invention may contain vitamins, hormones, and other nutritional supplements. Next, typical forms, intake amounts, and intake methods of the functional food of the present invention will be illustrated.
食品形態 摂取量および摂取方法
ドロップ １日４回各回１〜３個
（２５０ｍｇ／１個含有）
ドリンク剤 １日３〜６回各回１００ｍｌ’（０，
５％液ン
なあ、ここに記述した摂取量、摂取回数は単なる目安で
あり、Ｌ−カルノシンは前述のように極めて安全な物質
であるから適宜増減することは何ら差し支えない。Food form: Amount and method of intake Drops: 1 to 3 pieces each time, 4 times a day (contains 250 mg/1 piece) Drink: 100 ml' (0,
As for the 5% solution, the intake amount and frequency of intake described here are just a guideline, and as L-carnosine is an extremely safe substance as mentioned above, there is no problem in increasing or decreasing it as appropriate.
Ｌ−カルノシンの１ｇは２５℃で３．１ｍｌの水に溶解
するほど水に極めて易溶性であるため当業界で慣用の方
法によって容易にドリンク剤を得ることができる。但し
Ｌ−カルノシンは酸性で不安定であるので酸性物質の混
入は好ましくない。ドロップは結合剤例えばシロップ、
アラビアゴム、ゼラチン、ソルビット、トラガント、ま
たはポリビニルピロリドン、賦形剤例えば乳糖、とうも
ろこしデンプン、リン酸カルシウム、ソルビットまたは
グリシン、潤滑剤例えばステアリン酸マグネンウム、ポ
リエチレングリコーノベヒドロキシプロピルメチルセル
ロースまたはシリカ、崩壊剤例えばラウリル硫酸す）
ＩＪウムなどを使用し当業界での慣用の方法で製造する
。L-carnosine is extremely soluble in water, so that 1 g of L-carnosine dissolves in 3.1 ml of water at 25°C, and therefore a drink can be easily obtained by a method commonly used in the art. However, since L-carnosine is acidic and unstable, contamination with acidic substances is not preferred. The drop is a binder such as syrup,
gum arabic, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone, excipients such as lactose, corn starch, calcium phosphate, sorbitol or glycine, lubricants such as magnenium stearate, polyethylene glycol, hydroxypropyl methylcellulose or silica, disintegrants such as lauryl sulfate. )
It is manufactured by a method commonly used in the industry using IJum or the like.
摂取によって生体機能調節効果が予想される疾患および
症状
り一力ルノシンの免疫調節と組織修復促進の生体防衛整
合なホメオスタシス増強作用は特定の標的臓器のない全
身的、普遍的な、かつ臓器生理機能の上位概念の生理機
能である。したがってその減衰は脆弱な部分に機能的、
器質的異常を起こし体調の不調和、疾病の原因となる。Diseases and symptoms where ingestion is expected to have a biological function regulating effect Lunosine's immunomodulatory and tissue repair promoting biological defense consistent homeostasis enhancing effects are systemic, universal, and organ physiological functions without specific target organs. It is a superordinate concept of physiological function. Therefore, the attenuation is functional to the vulnerable area,
It causes organic abnormalities, causing physical imbalances and diseases.
Ｌ−カルノシンによるホメオスタシスの人為的増強はホ
メオスタシスによる制御可能な閣内にある機能的、器質
的異常に対し再構築に作用する。その作用は全に作用し
て個の異常を修復する作用で、細分化した個に対症化学
療法を行う従来の医学概念とは逆の概念に基づく治癒作
用である。日常起こる生理機能の異常、不調和に対して
Ｌ−カルノシンを含有する機能性食品を摂取することに
よりつぎのような機能的、器質的生理機能の再溝築、維
持が可能となる。Artificial enhancement of homeostasis by L-carnosine acts to reconstruct functional and organic abnormalities within the controllable framework of homeostasis. Its action is to repair abnormalities in the individual by acting on the entire body, which is a healing action based on a concept opposite to the conventional medical concept of administering symptomatic chemotherapy to each individual. By ingesting functional foods containing L-carnosine for abnormalities and disharmony in physiological functions that occur on a daily basis, it becomes possible to reestablish and maintain the following functional and organic physiological functions.
（１）臓器生理機能再構築、各科疾病の予後回復促進、
各科外科創の始点促進、機能回復促進。(1) Reconstruction of organ physiological functions, promotion of prognosis recovery of various diseases,
Promote the starting point of surgical wounds in various departments and promote functional recovery.
（２）免疫調節、組織修復促進の生体防衛作用によるＨ
ＩＶ感染後エイズ発症の予防、喘息、ロイマチスなどの
１り原病の治療、放射線、抗腫瘍剤、抗生物質、免疫抑
制剤その他のホメオスタシス機能低下を賦活する作用に
よる副作用、その他の感染症の予防と治療、免疫促進剤
の効果増強、運動機能の老化、免疫機能の老化、桟器の
老化（白内障など）の予防と治療、結合組織、骨の老化
（骨粗しよう症、骨折、皮膚、血管の老化など）に関係
する疾患の治療。(2) H due to biological defense effects such as immune regulation and promotion of tissue repair
Prevention of the onset of AIDS after IV infection, treatment of primary diseases such as asthma and leumatitis, prevention of side effects caused by radiation, antitumor agents, antibiotics, immunosuppressants, and other agents that activate homeostatic dysfunction, and prevention of other infectious diseases. and treatment, enhancement of the effect of immune promoters, aging of motor function, aging of immune function, prevention and treatment of aging of organs (cataracts, etc.), connective tissue, aging of bones (osteoporosis, bone fractures, skin, blood vessels, etc.) treatment of diseases related to aging, etc.).
（３）虚食など心身症の治療
つぎに本発明の実施例および試験例をあげて本発明の詳
細な説明する。ただし本発明はこれらの例によって限定
されるものではない。(3) Treatment of psychosomatic disorders such as starvation The present invention will now be described in detail with reference to Examples and Test Examples. However, the present invention is not limited to these examples.
実施例１．（ドロップ）
成 分
り一力ルノシン
ＲＰＣ（ハイプロピルセルロース）
グラニユー糖
ステアリン酸マグネシウム
香料
着色料
５０ｇ
０ｇ
５０ｇ
０ｇ
微量
微量
水を加えて １０００ｄ
この処方により１個１ｇのゼＩＪ −１０００個をつく
った。Example 1. (Drop) Ingredients Riichiriki Lunosine RPC (hypropyl cellulose) Granulated sugar Magnesium stearate Flavor coloring agent 50g 0g 50g 0g Add trace amount of water 1000d Using this recipe, 1000 pieces of ZeIJ-1, each weighing 1g, were made.
実施例３．（ドリンク剤）
成分
り一力ルノシン ０．５ｇグラニユ
ー糖 ５ｇ香料 微
量
着色料 微 量この処方に
より、打錠機を使用
ドロップ１０００個をつくった。Example 3. (Drink) Ingredients Riichiriki Lunosin 0.5g Granulated sugar 5g Flavoring Small amount Coloring agent Small amount Based on this recipe, 1000 drops were made using a tablet machine.
実施例２．（ゼリー）
成 分
り一力ルノシン
ゼラチン
グラニユー糖
水飴
香料
０００ｇ
して１個１ｇの
５０ｇ
ｇ
００ｇ
００ｇ
微 量
水を加えて １００遊
試験例１゜
Ｌ−カルノシンの抗体産生賦活作用、過酸化脂質生成抑
制効果および老化に伴う運動能力の低下に対する賦活作
用について試験した。Example 2. (Jelly) Ingredients Richiryoku Lunosine gelatin Granulated sugar starch syrup Flavoring 000g Add 50g of 1g of 1 piece 00g 00g 100% of water Test example 1゜ Antibody production activation effect of L-carnosine, lipid peroxide The inhibitory effect on production and the activating effect on the decline in exercise capacity associated with aging were tested.
Ａ、抗体産生賦活作用
溶血プラーク法（ＰＦＣ法）〔カニンガム法（Ｃｕｎｎ
ｉｎｇｈａｍ法）を改良した液体室−スライド法〕によ
りプラーク生成細胞（Ｐ Ｆ Ｃ，ｐｌａｑｕｅ ｆｏ
ｒｍｉｎｇｃｅｌｌ）数を計測し、抗体産生能を調べた
。感作には５週齢、３０週齢各−群５匹の未処置ＤＤＹ
マウスと、予めＬ−力ルノンンの１００ｍｇ／ｋｇ／日
Ｓ、Ｃ，を８日間投与した一群５匹のマウスに羊赤血球
（Ｓ ＲＢＣＸｓｈｅｅｐ ｒｅｄ ｂｌｏｏｄ ｃｅ
ｌｌ） Ｉ Ｘ １０８個を尾静脈かる注入した。４日
後に肺臓細胞を取り出して５ＲＢＣ，補体とともにチェ
ンバーに封入し、３７℃、１時間で生成するプラーク数
を計測した。A. Antibody production activation hemolytic plaque method (PFC method) [Cunningham method
Plaque forming cells (PFC, plaque fo.
rmingcell) number and examined the antibody production ability. For sensitization, 5 week old and 30 week old untreated DDY were used in each group.
Mice were treated with sheep red blood cells (S RBCXsheep red blood ce
ll) 108 IX were injected through the tail vein. After 4 days, the lung cells were taken out and sealed in a chamber together with 5RBC and complement, and the number of plaques formed was counted at 37° C. for 1 hour.
第 ２ 表
抗体産生賦活作用
数値は５匹のマウスの平均±Ｓ、Ｄ、であり、３００週
齢正常群；ま５週齢のマウスに比較してＰく０．００１
の危険率で有意にＰＦＣが低下し、Ｌ−カルノシンを投
与した群ではＰ＜０．００１の危険率で有意に賦活した
。Table 2 Antibody production activation effect values are the average ± S, D of 5 mice, 300 week old normal group; P 0.001 compared to 5 week old mice.
PFC was significantly decreased with a risk ratio of P<0.001 in the group administered with L-carnosine.
Ｂ、過酸化脂質生成抑制効果
ＴＢＡ （チオバルビッール酸）試験によって組織の過
酸化度を測定した。ＤＤＹマウスの５週齢の雄１０匹を
２群に分けた。対照としては生理食塩水−ｔＯ，１ｍｆ
、Ｌ−カルノシンは２５０ｍｇ／ｋｇをそれぞれ皮下に
７日間投与した。投与最終日に動物を放血致死させ、脳
を取り出し、１０％ホモジネートとした。１匹の動物の
ホモジネートを１ｍｌずつ２検体とした。検体を３７℃
で２０分間好気的にインキュベートし、１０％トリクロ
ロ酢酸溶液１ｍｌを加えてタンパク質を除き、遠心上澄
中の１蔵をとり、０．７％チオバルビッール酸溶液を１
彪加え、沸騰水浴中で１０分間加熱した後、５３０ｎｍ
の吸光度を測定した。B. Effect of inhibiting lipid peroxide production. The degree of peroxidation in tissues was measured by the TBA (thiobarbic acid) test. Ten 5-week-old male DDY mice were divided into two groups. As a control, physiological saline-tO, 1 mf
, L-carnosine was administered subcutaneously at 250 mg/kg for 7 days. On the final day of administration, the animals were sacrificed by exsanguination, and the brains were removed and made into a 10% homogenate. Two 1 ml samples of homogenate from one animal were prepared. Sample at 37℃
After incubating aerobically for 20 minutes at
After adding Biao and heating in a boiling water bath for 10 minutes, 530 nm
The absorbance was measured.
つぎの表に示したように、Ｌ−カルノシンを投与した動
物では、過酸化脂質の生成が７８％と有意に抑制された
。As shown in the following table, in animals administered with L-carnosine, the production of lipid peroxide was significantly suppressed by 78%.
第３表
Ｃ９老化に伴う運動能力の低下に対する賦活作用雄性、
１２週齢のマウスを１群２０匹前後とし、５匹ずつのケ
ージに入れて、０．１５％となるようＬ−カルノシンを
水道水に溶解して自由に摂取させた。計算上２００ ｍ
ｇ／ｋｇ／日経口投与となる値である。対照群は水道水
とし、両群とも固形飼料は自由に摂取させた。２０週齢
からトレッドミル上で走行練習をさせ、−週間に一度の
割合で３５ｍ／分の条件で１０分間を限度として、極限
まで走行させた。後部に電極が設置され、スピードダウ
ンすると刺激を受ける仕組みである。それぞれのマウス
の限界時間を測定し、５分以下、５分から１０分、１０
分以上走行するグループに分類して、それぞれの割合を
％であられした。Table 3 C9 Activating effect on the decline in athletic ability due to aging Male,
A group of about 20 12-week-old mice were placed in cages of 5 mice each, and allowed to freely ingest L-carnosine dissolved in tap water to a concentration of 0.15%. Calculated 200 m
This value corresponds to oral administration of g/kg/day. The control group received tap water, and both groups were given solid food ad libitum. From the age of 20 weeks, the mice were allowed to practice running on a treadmill, running once a week for a maximum of 10 minutes at a speed of 35 m/min. Electrodes are installed at the rear of the vehicle and are stimulated when the vehicle slows down. Measure the limit time of each mouse, 5 minutes or less, 5 minutes to 10 minutes, 10 minutes.
Classified into groups that run for more than 1 minute, the respective percentages were calculated as a percentage.
第４表
表に示したのはマウスが３０週齢に達した時の値である
が、水道水で飼育した群では走行時間５分以内が半数以
上であった。それに対しＬ−カルノシンを摂取させた群
では走行時間が延長し、半数以上が１０分以上走行して
も余力を残し、運動能力が賦活した。Table 4 shows the values when the mice reached 30 weeks of age, and in the group raised with tap water, more than half of the mice ran for less than 5 minutes. On the other hand, in the group that took L-carnosine, the running time was longer, and more than half of the participants had residual strength even after running for more than 10 minutes, and their athletic ability was activated.
Ｌ−カルノシンの有する抗体産生賦活作用、過酸化脂質
抑制効果および老化に伴う運動能力の低下に対する賦活
作用から、Ｌ−カルノシンを含有する機能性食品の摂取
によって老化抑制にすぐれた効果が得られることが予想
される。L-carnosine has an effect of activating antibody production, suppressing lipid peroxide, and activating the decline in exercise capacity associated with aging, so that ingestion of functional foods containing L-carnosine can have an excellent effect in suppressing aging. is expected.
試験例２゜
９０才の女性
老衰以外に診断のつく疾患はないが、ベツドに寝たきり
の入院患者である。虚食であり、会話応答および表情の
反応もなく諸反応が極めて弱い。Test Example 2 A 90-year-old woman had no diagnosable disease other than senility, but was a bedridden inpatient. The patient was starved, and his reactions were extremely weak, with no conversational or facial responses.
Ｌ−カルノシン含有ドロップ（２５０ｍｇ／１個含有）
を１日４回、各回１個摂取させた。１４４日目ら１日４
回、各回２個に増量した。７日目には１日通算２時間程
度ベツドから起き上がれる程で、会話応答もできる程に
元気が出た。２００日目は院内の散歩や、同室の患者と
も進んで会話をするようになり、軽運動によるリハビリ
テーションに参加することが可能になるまでに回復した
。L-carnosine containing drop (contains 250mg/1 piece)
The subjects were given 4 times a day, 1 piece each time. 144th day 1 day 4
The amount was increased to 2 pieces each time. On the seventh day, I was able to get out of bed for about two hours a day, and I felt so energetic that I could even respond to a conversation. On the 200th day, he was able to walk around the hospital and talk to patients in his room, and he had recovered to the point where he was able to participate in rehabilitation through light exercise.
入院中はドロップと併用する薬剤は一切使用しなかった
。（退院後も摂取を継続させている。）試験例３゜
５８才の女性
卵巣癌の摘出手術を受けた。５ｋｇの巨大腫瘍であった
。手術の１０日前からし一力ルノシンのドリンク剤（１
１ｔ！１００ｍ、 ０．５ ｇ含有）を１日４回、各回
１瓶を飲用させた。術後の経過は極めて順調であった。During my hospitalization, I did not use any drugs in combination with the drops. (The intake was continued even after being discharged from the hospital.) Test Example 3: A 58-year-old woman underwent surgery to remove ovarian cancer. It was a huge tumor weighing 5 kg. Starting 10 days before surgery, take Shiichiriki Lunosine drink (1
1t! (100m, containing 0.5 g) was administered four times a day, one bottle each time. The postoperative course was extremely uneventful.
手術側の治癒は極めて早く５日目には抜糸した。腹水貯
留はなく、術後の苦痛も少なく、巨大侵襲後の生理機能
の再建は速やかであった。応答も極めて明快で、１０日
後には院内の散歩が可能となり、その後の経過も良好で
４０日後には退院することができた。かかる巨大手術後
には腹水貯留、衰弱、回復の遅延などの症状を起こすの
が普通であるが、このような症状は全く見られず生理機
能の再建は速やかであった。抗腫瘍剤や免疫調節剤は使
用しなかった。（退院後もドリンク剤１日１瓶の飲用を
継続させている。）試験例４゜
５６オの男性
肝臓癌（雀卵大の腫瘍）のため肝葉の切除手術を受けた
。手術の１０日前からＬ−カルノシンのドリンク剤（前
記と同じ）を１日４回、１回ｌ瓶を飲用させた。ドリン
ク剤と併用する薬剤は使用しなかった。The surgical side healed extremely quickly, and the stitches were removed on the fifth day. There was no ascites retention, there was little postoperative pain, and physiological function was quickly restored after the massive invasion. The patient's response was very clear, and he was able to walk around the hospital after 10 days, and his subsequent progress was good, and he was discharged from the hospital 40 days later. After such a major surgery, it is normal to experience symptoms such as ascites retention, weakness, and delayed recovery, but these symptoms were not observed at all, and physiological functions were quickly restored. No antitumor or immunomodulatory agents were used. (Even after being discharged from the hospital, he continued to drink one bottle of the drink a day.) Test Example 4: A 56-year-old man underwent surgery to remove a liver lobe due to liver cancer (a sparrow-egg-sized tumor). Starting 10 days before the surgery, the rats were given a L-carnosine drink (same as above) four times a day, one liter bottle at a time. No drugs were used in conjunction with the drink.
術後の創傷部の始点経過は極めて速やかで４日目には抜
糸した。創傷部の仕上がりは極めて順調であった。抜糸
当日から院内の軽い散歩を自発的に行った。体力、気力
の回復も著しく術後２５日目で退院することができた。The initial progress of the postoperative wound was extremely rapid, and sutures were removed on the 4th day. The wound area was finished very well. From the day the stitches were removed, the patient voluntarily took a light walk around the hospital. The patient's physical strength and energy recovered significantly and he was able to be discharged from the hospital 25 days after the surgery.
通常の肝臓手術後に見られる倦怠、衰弱、回復の遅延な
どの症状は全く起こらなかった。退院後も１日２回、１
回１瓶のし一力ルノシンのドリンク剤を飲用させた。体
力の回復も極めて順調で、６０日後には会社勤務に復帰
した。None of the symptoms of fatigue, weakness, or delayed recovery that are seen after normal liver surgery occurred. Even after discharge from the hospital, twice a day, 1
Each patient was given a bottle of Shiichiriki Lunosin drink. His physical strength recovered extremely well, and he returned to work after 60 days.
試験例５゜
７５才の男性
右膝蓋を骨折し、入院手術後にＬ−カルノシンのドリン
ク剤（前記と同じ）を１日４回、１回１瓶を飲用させた
。術後２８日目から開始したリハビリテーション機能の
訓練中、膝関節の伸展は極めて速やかで回復が早かった
。リハビリテーション開始１０日後には自刃で階段を昇
降できる程度に回復した。心身爽快で社会復帰を早めた
。（退院後も１日２回、１回１瓶の飲用を継続させてい
る。）
試験例６゜
１０才の男児
早産未熟児であったが、以後の発育も不良で虚弱体質の
まま１０才になった。気管支喘息、突発性発疹が強かっ
た。風邪を引きやすく、脆弱な体質であった。体重は２
４ｋｇで同年令の男子の平均体重の３２．２±６．０
ｋｇに達しなかった。Ｌ−カルノシンのドロップ（前記
と同じ）を１日４回、１回２個を摂取させた。ドロップ
剤と併用する薬剤は一切使用しなかった。Test Example 5: A 75-year-old man suffered a fracture of his right patella, and after being admitted to the hospital for surgery, he was given an L-carnosine drink (same as above) four times a day, one bottle at a time. During rehabilitation function training, which began on the 28th day after surgery, the knee joint was able to extend very quickly and recovery was quick. Ten days after rehabilitation began, he was able to walk up and down the stairs using his own knife. It was refreshing both physically and mentally and helped them return to society more quickly. (Even after being discharged from the hospital, he continued to drink one bottle twice a day.) Test Example 6: A 10-year-old boy was born prematurely, but his growth was poor and he remained in a weak condition until the age of 10. Became. He had severe bronchial asthma and sudden rash. He was prone to catching colds and had a fragile constitution. Weight is 2
4kg is the average weight of a male of the same age, 32.2±6.0
It did not reach kg. L-carnosine drops (same as above) were ingested four times a day, two at a time. No drugs were used in combination with the drops.
Ｌ−カルノシンのドロップを与えはじめてから３０日目
には体重に１．５ｋｇの増加が見られ、日常生活は敏捷
かつ活発となった。３５日目には突発性発疹の治癒が観
察された。Ｌ−カルノシンのドロップを与えはじめてか
ら２ケ月目には体重は更に３．５ ｋｇ増加した。１年
６ケ月を経過し、例年のインフルエンザの流行の季節に
も感染せず、気管支喘息は治癒したとみられる。体重は
３２ｋｇとなり、１１才の男子の平均体重の３６．０±
１．７ ｋｇにちかくまで発育した。体重の増加は以後
も順調である。発育不良、脆弱体質、喘息、突発性発疹
などの症状は完全に改善された。ドロップの１日２回、
１回１個の摂取はずっと続けた。副作用とみられる症状
は全く観察されていない。Thirty days after starting to give L-carnosine drops, his weight increased by 1.5 kg, and his daily life became alert and active. Healing of the sudden rash was observed on the 35th day. Two months after starting the L-carnosine drops, her weight increased by an additional 3.5 kg. One year and six months have passed, and he has not been infected during the usual influenza season, and his bronchial asthma appears to have been cured. His weight was 32 kg, which is 36.0± the average weight for an 11-year-old boy.
It grew to almost 1.7 kg. Weight gain has been steady since then. Symptoms such as poor growth, fragile constitution, asthma, and sudden rashes have completely improved. Drop twice a day,
I continued to take one at a time. No symptoms that could be considered side effects were observed.
試験例７゜
６３才の男性、団体役員、病歴４年
４年前に胸郭整形術を行い、２年前に胃潰瘍で胃の部分
切除を行い、手術後より体質虚弱となる。Test Example 7゜63-year-old male, organization executive, medical history: 4 years.He had undergone thoracic surgery 4 years ago, and had partial gastric resection due to gastric ulcer 2 years ago, and his constitution had become weaker since the surgery.
現症は圓症状で食欲は通常である。易疲労性、不眠にわ
ずられされ、持続力がなく、背筋にしびれの症状、腹部
の疼痛が頻発する。デスクワークの労働時間は１日３時
聞時間度とする。内科で再三精密検査をしたが全く異常
所見は発見されなかった。Ｖ Ｂ ｌ ２の投与を受け
ていたが効果はなかった。The current symptoms are round symptoms and appetite is normal. The patient suffers from fatigue, insomnia, lack of endurance, and frequent symptoms of numbness in the back muscles and pain in the abdomen. Working hours for desk work are 3 hours per day. The patient underwent repeated detailed examinations at the internal medicine department, but no abnormal findings were found. He had been receiving V B l 2, but it had no effect.
心身症と診断され心理療法も行ったが効果はなかった。He was diagnosed with a psychosomatic disorder and underwent psychological therapy, but it had no effect.
Ｌ−カルノシンのドリンク剤（前記と同じ）を１日４回
、１回１瓶を飲用させた。男性ホルモン剤以外の薬剤は
一切使用しなかった。７ロー頃より食欲が増加し、背部
のしびれ感は消失した。The L-carnosine drink (same as above) was given 4 times a day, 1 bottle at a time. No drugs other than male hormones were used. From around 7th row, my appetite increased and the numbness in my back disappeared.
１０日後には不定愁訴、内臓の疼痛、違和感も消失、治
癒し、熟睡できるようになった。体重はドリンク剤を飲
み始めてから１５日目には２ｋｇ増加した。−日の就労
時間を自発的に延長し、８時間とした。精神集中が可能
となり、作業能力も向上した。心身ともに快調、積極的
、意欲的となり、心身症は治癒したと診断された。ドリ
ンク剤を飲み始めてから２０日後には２０日間の欧米の
出張旅行に出発し、過密な旅行日程によく耐えた。その
間ドロップ剤（前記と同じ）を１日２回、１回２個の摂
取を続けた。旅行中、帰国後も異常は自覚しなかった。After 10 days, the patient's indeterminate complaints, visceral pain, and discomfort disappeared, he was cured, and he was able to sleep soundly. My weight increased by 2 kg on the 15th day after I started taking the drink. - Voluntarily extended working hours to 8 hours. It became possible to concentrate mentally and improve work ability. He felt well both physically and mentally, became active and motivated, and was diagnosed as having been cured of his psychosomatic illness. Twenty days after he started taking the drink, he departed on a 20-day business trip to Europe and America, and endured the hectic travel itinerary well. During that time, he continued to take the drops (same as above) twice a day, two at a time. During the trip, I did not notice any abnormalities even after returning home.
ドリンク剤１日２本を引きつづき摂取している。He continues to take two drinks per day.
試験例８゜
５９才の男性、団体役員、病歴２年
胃潰瘍で胃全摘手術を行った。術後の経過は順調で退院
したが、退院後間もなく産金、内臓痛、体重減少、不眠
、背部のしびれ感が著しく不定愁訴が強く （退院時の
５６ｋｇが４６ｋｇに減少）、芝症状であり、易疲労性
で１日殆ど横臥する。また無意欲である。会社を退職し
、自宅療養を続け２年間経過した症例である。その間、
内科に短期入院して精密検査を受けたが、内科的に異常
所見はみられず、心身症と診断された。心療内科にも６
か月通院したが全く効果はなかった。Ｌ−カルノシンの
ドリンク剤（前記と同じ）を１日４回、１回１瓶を飲用
させた。飲用開始１０日位で食欲は徐々に回復し、不定
愁訴は次第にな（なった。約２５日後には腹痛は消失し
、食欲は旺盛となり、体重はＬ−カルノシンドリンク剤
の飲用開始前より３ｋｇ増加した。日常生活も意欲的、
行動的かつ積極的に変化した。４０日後よりＬ−カルノ
シンドリンク剤の１日２回、１回１瓶の飲用を続け・て
いる。ドリンク剤に併用する薬剤は−切使用していない
。会社勤務に復帰した。Test Example 8 A 59-year-old man, an organization executive, had a 2-year history of gastric ulcer and underwent total gastrectomy. The postoperative course was uneventful and he was discharged from the hospital, but shortly after discharge, he developed symptoms such as pain, visceral pain, weight loss, insomnia, and a feeling of numbness in his back. , fatigue easily and lie down most of the day. He is also unmotivated. This is a case in which the patient retired from work and continued to receive treatment at home for two years. meanwhile,
He was admitted to the internal medicine department for a short period of time and underwent a thorough examination, but no abnormal findings were found, and he was diagnosed with a psychosomatic disorder. Also for psychosomatic medicine 6
I visited the hospital for months, but there was no effect at all. The L-carnosine drink (same as above) was given 4 times a day, 1 bottle at a time. About 10 days after starting taking the L-carnosine drink, her appetite gradually recovered, and her indeterminate complaints gradually disappeared.About 25 days later, her abdominal pain disappeared, her appetite became strong, and her weight was 3 kg lower than before she started taking the L-carnosine drink. Increased. Daily life is also ambitious.
Changed behaviorally and proactively. After 40 days, the patient continued to take L-carnosine drink twice a day, one bottle at a time. No drugs were used in combination with the drink. I returned to work at the company.
試験例９゜
４４才の男性、通信社勤務
食欲極めて細く、易疲労、消極的、稟症状、インポテン
ツである。２年以来***渉は全くない。Test Example 9: A 44-year-old man works at a news agency.He has a very small appetite, easily fatigues, is passive, has symptoms of illness, and is impotent. I haven't had any sex since 2 years.
内科への短期入院で精密検査の結果は特別の疾病はない
といわれた。ＶＢ、□とホルモンによる療法を続けたが
全く効果はなかった。Ｌ−カルノシンのドリンク剤（前
記と同じ）を１日４回、１回１瓶を飲用させた。５ロー
頃より食欲旺盛となる。After a short stay at an internal medicine clinic, a thorough examination revealed no particular illness. I continued therapy with VB, □ and hormones, but there was no effect at all. The L-carnosine drink (same as above) was given 4 times a day, 1 bottle at a time. Appetite starts to increase around 5 rows.
体重は２ ｋｇ増加し、生活態度も明るくなった。My weight has increased by 2 kg, and my attitude towards life has become brighter.
１０日ローより行動は積極的、意欲的となり責症状はな
く、談笑するようになり、性格的に大きく変化した。２
０日ローは会社勤務も正常化した。From the 10th low onwards, his behavior became more active and motivated, he showed no signs of remorse, started chatting, and his personality changed significantly. 2
Work at the company has returned to normal for Day 0.
以前には全く興味を持たなかったスポーツにも興味を示
し、ゴルフコンペにも参加するようになった。またドリ
ンク剤飲用開始３０ロー頃から月１回位の***渉をもつ
ようになった。He has developed an interest in sports that he had no interest in before, and has started participating in golf competitions. Also, since I started taking the drug around 30 years old, I started having sex about once a month.
試験例１０゜
４８才の女性
乳癌と診断され、右***の手術を行った。５ケ月後に再
発し、再手術後に潰瘍化した。自殺未遂で癌ホスビスに
収容された。産金で、寞質で部屋を暗くして１日中横臥
するのみであった。癌の療法は行なわなかった。Ｌ−カ
ルノシンのドロップ（前記と同じ）を１日合計３ｇにな
るように随時摂取させた。男性ホルモン剤以外の薬剤は
一切使用しなかった。１０日ローより食欲は急激に増加
の傾向がみられ１回に２食分を要求するようになった。Test Example 10 A 48-year-old woman was diagnosed with breast cancer and underwent surgery on her right breast. Five months later, the tumor recurred and ulcerated after reoperation. He was admitted to Cancer Hospice after attempting suicide. Due to his poor health, he would only lie down all day in a darkened room. No cancer therapy was given. L-carnosine drops (same as above) were ingested at any time for a total of 3 g per day. No drugs other than male hormones were used. After the 10-day low, his appetite started to increase rapidly, and he started requesting two meals at a time.
また部屋を明るくし、身だしなみをととのえるようにな
った。看護婦との会話もよくするようになり、明るい笑
いが見られるようになった。She also began to brighten up her room and take better care of herself. He started to talk more often with the nurses and was able to smile brightly.
また院内外の散歩は毎日欠かさないようになり、癌患者
特有のズ症状は全く消失した。ドロップの摂取開始後５
５日回心退院したが、引き続き外来で潰瘍の治療を続け
ることとした。社会復帰し家事に従事した。In addition, I no longer miss walking in and out of the hospital every day, and the symptoms characteristic of cancer patients have completely disappeared. 5 after starting drop intake
Although the patient was converted and discharged from the hospital on the 5th day, it was decided that he would continue to receive treatment for the ulcer as an outpatient. He returned to society and engaged in housework.
試験例１１゜
下記の患者にＬ−カルノシンのドリンク剤（前記と同じ
）を飲用させて、放射線照射による副作用の予防と治療
について試験した。Test Example 11 The following patients were given an L-carnosine drink (same as above) to test the prevention and treatment of side effects caused by radiation.
症例 年令 性別 診 断
Ａ ５６ 男 ***癌８ ４５
女 乳癌
Ｃ４２男 頚部癌
Ｄ ４６ 女 乳癌
Ｅ ４２ 男 上咽頭癌放射線看は２
００ ｒａｄ／日とし、総線量は５０００ｒａｄ／１ク
ールとした。ホメオスタシスを増強するため放射線治療
開始７日前からドリンク剤を１日４回、１回２本を飲用
させ、以後も飲用を継続させた。症例Ａ、Ｂ５Ｃ５Ｅで
は食欲、体重に影響がなく、また照射終了時の体重およ
び白血球数は照射前と変わず正常の範囲であり、副作用
症状はなかった。症例りでは総線量４６００ｒａｄで食
欲を失い、めまい、虚脱感、嘔感、不眠、嘔吐、腹痛な
どの症状があり、白血球数が３０００に減少したので照
射を中止した。照射中止後もドリンク剤の飲用をつづけ
、照射中止７日後には前記の症状は完全に消失した。ド
リンク剤の効果を有効に発揮させるには放射線治療開始
７日前からドリンク剤の飲用を毎日つづけること、およ
び５０００ｒａｄの第１回照射終了後も毎日ドリンク剤
の飲用をつづけ、つぎの照射は２０〜２５日のインター
バルをおいて行うことにより、放射線照射による副作用
は完全に避けられるか、または大いに軽減されることが
わかった。Case Age Gender Diagnosis A 56 Male Lip cancer 8 45
Female Breast Cancer C 42 Male Cervical Cancer D 46 Female Breast Cancer E 42 Male Nasopharyngeal Cancer Radiology 2
00 rad/day, and the total dose was 5000 rad/1 course. In order to enhance homeostasis, the subjects were given a drink, two bottles at a time, four times a day starting 7 days before the start of radiotherapy, and continued to drink it thereafter. In cases A and B5C5E, there was no effect on appetite or body weight, and the body weight and white blood cell count at the end of irradiation remained in the normal range, unchanged from before irradiation, and there were no side effects. In one case, the patient lost appetite at a total dose of 4,600 rad, and had symptoms such as dizziness, weakness, nausea, insomnia, vomiting, and abdominal pain, and the white blood cell count decreased to 3,000, so irradiation was discontinued. Even after the irradiation was discontinued, the patient continued to take the drink, and the above-mentioned symptoms completely disappeared 7 days after the irradiation was discontinued. In order to effectively demonstrate the effect of the drink, it is necessary to continue drinking the drink every day from 7 days before the start of radiation treatment, and continue to drink the drink every day even after the first irradiation of 5,000 rad is completed, and the next irradiation should be done at 20 to 20 days. It has been found that by administering the treatments at 25-day intervals, the side effects of radiation exposure can be completely avoided or greatly reduced.
試験例１２゜
下記の患者にＬ−カルノシンのドリンク剤（前記と同じ
）を飲用させて、抗腫瘍剤による副作用の除去について
試験した。Test Example 12 The following patients were given an L-carnosine drink (same as above) to test for removal of side effects caused by the antitumor agent.
症例 年令 性別 診 断
ａ ４２ 女 乳癌術後
ｂ ４６ 男 頚Ｂ癌術後ｃ ４５
女 乳癌術後
ＭＴＸの２０ｍｇを点滴した。点滴７日前からドリンク
剤を１日４回、１回２本を飲用させ、以後も飲用を継続
させた。点滴の全期間を通じて虚脱、無動力症状、嘔吐
、産金、不定愁訴、白血球減少などの抗腫瘍剤による副
作用は完全に消去して食欲も旺盛となり、体重増加し、
癌病態の心身症は治應し、癌療養に積極的な生活を送る
ようになった。ＭＴＸの副作用により脱毛したり、脱毛
機新生する毛髪はら線状であるのが普通であるが、本発
明の機能性食品を摂取することにより、このような副作
用を予防することができる。また摂取しなかったために
このような副作用が起こった場合でも中途から摂取させ
ることによって治療することができ、摂取３力月後には
毛髪は生え揃い美しくなることがわかった。Case Age Gender Diagnosis a 42 Female Breast cancer surgery b 46 Male Cervical B cancer surgery c 45
Female 20mg of MTX was infused after breast cancer surgery. Seven days before the infusion, the subjects were allowed to drink the drink 4 times a day, 2 bottles at a time, and continued to drink it thereafter. During the entire period of infusion, the side effects caused by the antitumor drug, such as weakness, akinesia, vomiting, weight loss, indeterminate complaints, and decreased white blood cells, completely disappeared, and the patient also had a good appetite and gained weight.
The psychosomatic symptoms associated with the cancer have been cured, and the patient has begun to lead an active life with cancer treatment. The side effects of MTX usually result in hair loss or new hair growth, but such side effects can be prevented by ingesting the functional food of the present invention. In addition, even if such side effects occur due to not taking the drug, it can be treated by starting the drug midway through the intake, and it has been found that hair grows back and becomes beautiful after 3 months of intake.
放射線による副作用の予防の場合と同様に、点滴開始７
日前からドリンク剤を毎日飲用させること、および２０
〜２５日のインターバルをとって次回の点滴を行うこと
によって、抗腫瘍剤による副作用除去の有効性は大いに
増強されることがわかった。As in the case of prevention of side effects due to radiation, starting the infusion 7
Have the drink drink every day from 20 days in advance, and
It has been found that the effectiveness of eliminating side effects caused by the antitumor agent is greatly enhanced by performing the next infusion at an interval of ~25 days.
Ｌ−カルノシンを必須成分として含有する本発明の機能
性食品を摂取することにより、体調調節、生体防御の増
強、疾病の予防、疾病の回復、老化抑制などの効果が得
られる。By ingesting the functional food of the present invention containing L-carnosine as an essential component, effects such as regulating physical condition, enhancing biological defense, preventing disease, recovering from disease, and suppressing aging can be obtained.
手続補正書 ２、−３ １、事件の表示 昭和６３年特許願第１３９６７７号 ２、発明の名称 機能性食品 ３、補正をする者 事件との関係Procedural amendment 2, -3 1.Display of the incident 1986 Patent Application No. 139677 2. Name of the invention functional food 3. Person who makes corrections Relationship with the incident
Claims (7)
有することを特徴とする機能性食品。(1) A functional food characterized by containing L-carnosine or its salt as an essential component.
１）項記載の機能性食品。(2) Claim No. 1 (2) Used for psychosomatic disease treatment
Functional food described in section 1).
（１）項記載の機能性食品。(3) The functional food according to claim (1), which is used for strengthening and improving constitution.
）項記載の機能性食品。(4) Claim No. 1 (1) used for anti-aging purposes
Functional foods listed in ).
第（１）項記載の機能性食品。(5) The functional food according to claim (1), which is used for promoting surgical wound treatment.
防および除去用として使用する特許請求の範囲第（１）
項記載の機能性食品。(6) Claim No. 1 for use in preventing and eliminating side effects caused by radiation irradiation or antitumor drug administration
Functional foods listed in section.
の範囲第（１）項記載の機能性食品。(7) The functional food according to claim (1), which is used as an oral hair growth agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63139677A JPH0235057A (en) | 1988-04-26 | 1988-06-07 | Functional food |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63-103452 | 1988-04-26 | ||
| JP10345288 | 1988-04-26 | ||
| JP63139677A JPH0235057A (en) | 1988-04-26 | 1988-06-07 | Functional food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0235057A true JPH0235057A (en) | 1990-02-05 |
Family
ID=26444089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63139677A Pending JPH0235057A (en) | 1988-04-26 | 1988-06-07 | Functional food |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0235057A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0881371A (en) * | 1994-09-09 | 1996-03-26 | Suntory Ltd | Hematopoietic function promoter |
| EP0710485A1 (en) | 1994-09-09 | 1996-05-08 | Suntory Limited | Agents for stimulating hematopoiesis |
| JP2005120007A (en) * | 2003-10-16 | 2005-05-12 | Tokyoto Igaku Kenkyu Kiko | Vascularization inhibitor, therapeutic agent and prophylactic against disease followed by vascularization |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53127835A (en) * | 1977-04-12 | 1978-11-08 | Kaneshirou Nagai | Treating agent for burn |
| JPS58103321A (en) * | 1981-12-14 | 1983-06-20 | Kaneshiro Nagai | Remedy for hemorrhoids |
| JPS58164516A (en) * | 1982-03-25 | 1983-09-29 | Kaneshiro Nagai | Remedy for eczematoid skin disease and drug rash |
| JPS61186322A (en) * | 1985-02-13 | 1986-08-20 | Nippon Univ | Immunomodulator |
-
1988
- 1988-06-07 JP JP63139677A patent/JPH0235057A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53127835A (en) * | 1977-04-12 | 1978-11-08 | Kaneshirou Nagai | Treating agent for burn |
| JPS58103321A (en) * | 1981-12-14 | 1983-06-20 | Kaneshiro Nagai | Remedy for hemorrhoids |
| JPS58164516A (en) * | 1982-03-25 | 1983-09-29 | Kaneshiro Nagai | Remedy for eczematoid skin disease and drug rash |
| JPS61186322A (en) * | 1985-02-13 | 1986-08-20 | Nippon Univ | Immunomodulator |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0881371A (en) * | 1994-09-09 | 1996-03-26 | Suntory Ltd | Hematopoietic function promoter |
| EP0710485A1 (en) | 1994-09-09 | 1996-05-08 | Suntory Limited | Agents for stimulating hematopoiesis |
| JP2005120007A (en) * | 2003-10-16 | 2005-05-12 | Tokyoto Igaku Kenkyu Kiko | Vascularization inhibitor, therapeutic agent and prophylactic against disease followed by vascularization |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6007824A (en) | Natural composition and method for the treatment of sexual dysfunction | |
| US20050196434A1 (en) | Pharmaceutical composition and method for the transdermal delivery of magnesium | |
| US7674482B2 (en) | Method and compositions for potentiating pharmaceuticals with amino acid based medical foods | |
| JP4609875B2 (en) | healthy food | |
| JP4312402B2 (en) | Anti-depressant, anti-menopausal agent, anti-senile dementia agent, anti-Alzheimer agent | |
| JPH07507569A (en) | How to promote nitrogen retention in humans | |
| JP2002518440A (en) | Compositions and uses comprising β-hydroxy-β-methylbutyric acid and at least one amino acid | |
| CN102160664A (en) | Nutritious drink for children | |
| EP1083915B1 (en) | Compositions comprising molybdenum for enhancing protein anabolism and detoxification | |
| JP2001518481A (en) | Serotonin-containing preparations for oral administration and methods of use | |
| CN108771246B (en) | Composition for improving immunity and restoring physiological function of patients after operation or chemotherapy | |
| JP4484254B2 (en) | Amino acid composition | |
| JPH0235057A (en) | Functional food | |
| JPH05229938A (en) | Hypotensive agent | |
| JP7338835B2 (en) | Anti-cancer agent for reducing side effects | |
| US7998476B2 (en) | Method of treatment using Aspergillus oryzae protease | |
| CN109223766A (en) | Improve the composition and preparation process that microcirculation in human body improves the immunity of the human body | |
| RU2076731C1 (en) | Agent and method of organism nonspecific resistance increase at viscera morbidity | |
| RU2721605C1 (en) | Pharmaceutical composition for parenteral drop introduction | |
| Panda et al. | Zinc in Ayurvedic herbo-mineral products | |
| CA2385774A1 (en) | Composition to reduce food cravings and supress the appetite | |
| Tatyana et al. | Basedova disease (diffuse toxic goiter)-causes, symptoms, signs. Diagnosis and treatment of pathology | |
| TW201618767A (en) | Composition and method for treating restless legs syndrome and leg cramps | |
| US20110020463A1 (en) | Therapeutic agent for fibromyalgia syndrome and therapeutic agent for pain caused by muscle spasm | |
| RU2104012C1 (en) | Natural product-base pharmaceutical composition normalizing metabolic processes in organism |